论文部分内容阅读
Since the discovery of ERβ in 1996,much attention has been paid to studying its difference from ERα.In the following years,ERβ was comfirmed to associate with many diseases,such as cancer,cardiovascular disease,multiple sclerosis and Alzheimers disease.Therefore,selective estrogen receptor β agonists have therapeutic potentials in the treatment of those diseases[1].